BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21536130)

  • 1. Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil.
    Vignoli M; Nobili S; Napoli C; Putignano AL; Morganti M; Papi L; Valanzano R; Cianchi F; Tonelli F; Mazzei T; Mini E; Genuardi M
    Pharmacol Res; 2011 Sep; 64(3):242-8. PubMed ID: 21536130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers.
    Morganti M; Ciantelli M; Giglioni B; Putignano AL; Nobili S; Papi L; Landini I; Napoli C; Valanzano R; Cianchi F; Boddi V; Tonelli F; Cortesini C; Mazzei T; Genuardi M; Mini E
    Eur J Cancer; 2005 Sep; 41(14):2176-83. PubMed ID: 16182121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
    Dotor E; Cuatrecases M; Martínez-Iniesta M; Navarro M; Vilardell F; Guinó E; Pareja L; Figueras A; Molleví DG; Serrano T; de Oca J; Peinado MA; Moreno V; Germà JR; Capellá G; Villanueva A
    J Clin Oncol; 2006 Apr; 24(10):1603-11. PubMed ID: 16575011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer.
    Merkelbach-Bruse S; Hans V; Mathiak M; Sanguedolce R; Alessandro R; Rüschoff J; Büttner R; Houshdaran F; Gullotti L
    Oncol Rep; 2004 Apr; 11(4):839-43. PubMed ID: 15010882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil.
    Iacopetta B; Grieu F; Joseph D; Elsaleh H
    Br J Cancer; 2001 Sep; 85(6):827-30. PubMed ID: 11556832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of polymorphism of the tandem repeat sequence in the thymidylate synthase gene and the survival of stage III colorectal cancer patients receiving adjuvant 5-flurouracil-based chemotherapy.
    Park CM; Lee WY; Chun HK; Cho YB; Yun HR; Heo JS; Yun SH; Kim HC
    J Surg Oncol; 2010 Jan; 101(1):22-7. PubMed ID: 19798689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma.
    Toriumi F; Kubota T; Saikawa Y; Yoshida M; Otani Y; Watanabe M; Kumai K; Kitajima M
    Anticancer Res; 2004; 24(4):2455-63. PubMed ID: 15330198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients.
    Marcuello E; Altés A; del Rio E; César A; Menoyo A; Baiget M
    Int J Cancer; 2004 Dec; 112(5):733-7. PubMed ID: 15386371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation.
    Stoehlmacher J; Goekkurt E; Mogck U; Aust DE; Kramer M; Baretton GB; Liersch T; Ehninger G; Jakob C
    Cancer Lett; 2008 Dec; 272(2):221-5. PubMed ID: 18722050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients.
    Fernández-Contreras ME; Sánchez-Hernández JJ; González E; Herráez B; Domínguez I; Lozano M; García De Paredes ML; Muñoz A; Gamallo C
    Int J Oncol; 2009 Jan; 34(1):219-29. PubMed ID: 19082493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer.
    Ishida Y; Kawakami K; Tanaka Y; Kanehira E; Omura K; Watanabe G
    Anticancer Res; 2002; 22(5):2805-9. PubMed ID: 12530000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G>C SNP of thymidylate synthase with respect to colorectal cancer.
    Gusella M; Padrini R
    Pharmacogenomics; 2007 Aug; 8(8):985-96. PubMed ID: 17716232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Hitre E; Budai B; Adleff V; Czeglédi F; Horváth Z; Gyergyay F; Lövey J; Kovács T; Orosz Z; Láng I; Kásler M; Kralovánszky J
    Pharmacogenet Genomics; 2005 Oct; 15(10):723-30. PubMed ID: 16141798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer.
    Calascibetta A; Cabibi D; Martorana A; Sanguedolce G; Rausa L; Feo S; Dardanoni G; Sanguedolce R
    Anticancer Res; 2004; 24(6):3875-80. PubMed ID: 15736425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.
    Etienne MC; Chazal M; Laurent-Puig P; Magné N; Rosty C; Formento JL; Francoual M; Formento P; Renée N; Chamorey E; Bourgeon A; Seitz JF; Delpero JR; Letoublon C; Pezet D; Milano G
    J Clin Oncol; 2002 Jun; 20(12):2832-43. PubMed ID: 12065560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil.
    Fernández-Contreras ME; Sánchez-Prudencio S; Sánchez-Hernández JJ; García de Paredes ML; Gisbert JP; Roda-Navarro P; Gamallo C
    Int J Oncol; 2006 May; 28(5):1303-10. PubMed ID: 16596248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer.
    Mauritz R; Giovannetti E; Beumer IJ; Smid K; Van Groeningen CJ; Pinedo HM; Peters GJ
    Clin Colorectal Cancer; 2009 Jul; 8(3):146-54. PubMed ID: 19632929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.